Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of GS-9350 (cobicistat)-boosted atazanavir versus ritonavir-boosted atazanavir with emtricitabine/tenofovir in treatment-naïve HIV-1 infected adults
2009-016759-22Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cobicistat in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Gilead Sciences. Primary endpoint: HIV-1 RNA < 50 copies/mL at Week 48 (FDA snapshot analysis). Started Apr 2010; status: completed.
02
Drugs
cobicistat
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2009-016759-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016759-22.